Campbell & Co Investment Adviser’s Coherus Oncology CHRS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-54,229	Closed	-$203K	–	1119
2023 Q3	$203K	Buy	+54,229	New	+$250K	0.02%	848
2022 Q4	–	Sell	-19,934	Closed	-$192K	–	794
2022 Q3	$192K	Sell	19,934 -7,030	-26%	-$71.1K	0.04%	628
2022 Q2	$195K	Buy	+26,964	New	+$234K	0.05%	608
2021 Q1	–	Sell	-12,206	Closed	-$212K	–	448
2020 Q4	$212K	Sell	12,206 -5,200	-30%	-$92.6K	0.13%	349
2020 Q3	$319K	Buy	17,406 +4,300	+33%	+$80K	0.24%	165
2020 Q2	$234K	Buy	+13,106	New	+$222K	0.3%	166
2020 Q1	–	Sell	-18,666	Closed	-$336K	–	106
2019 Q4	$336K	Sell	18,666 -97	-0.5%	-$1.79K	0.1%	374
2019 Q3	$380K	Buy	18,763 +3,731	+25%	+$74.5K	0.14%	285
2019 Q2	$332K	Buy	+15,032	New	+$261K	0.15%	268

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's CHRS Position: Q4 2023 in Review

Campbell & Co Investment Adviser sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 54,229 shares — an estimated $203K sold.

Campbell & Co Investment Adviser first reported a position in CHRS in Q2 2019 and held it in 9 quarters. The position peaked at $380K in Q3 2019. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

Campbell & Co Investment Adviser reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
Campbell & Co Investment Adviser sold 54,229 Coherus Oncology shares in Q4 2023, an estimated $203K.
Campbell & Co Investment Adviser first reported a position in Coherus Oncology in Q2 2019 and held it in 9 quarters.
Campbell & Co Investment Adviser's Coherus Oncology position peaked at $380K in Q3 2019.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2023, filed 13 Feb 2024.